← Takaisin etusivulle

Tekoälymallien arviot osakkeelle
Johnson & Johnson markkinahintaan verrattuna

2026-05-22🇺🇸 S&Phealthcare
231.73 USD
52 viikon vaihteluväli
$149.04
$251.71

5 AI-mallia arvioi JNJ:n mediaaniksi 221.52 USD (-4.4% suhteessa spotiin 231.73 USD, mallien yksimielisyys 0.87). Analyytikkokonsensus 252.96 USD (24 analyytikkoa). Kokeellinen vertailu — ei sijoitusneuvontaa.

AI-konsensus

Mallin arvio
$221.52
Sis. 30 % analyytikkoankkurointi
Ero
-4.4%
Yksimielisyys
0.874/5 mallia ⚠
Raaka 0.81
Hajonta
σ 0.05
Analyytikkokonsensus
$252.96(24 analyytikkoa)
AI-yhteenveto
4 viidestä AI-mallia on negatiivisia JNJ. Huomioitavaa: Potential impact of patent expirations and increased generic competition on k... AI-konsensusarvio 221.52 4.4% alle nykyhinnan. Mallien yksimielisyys on korkea (0.87). Analyytikkokonsensus: 252.96 (AI -12.4%).
gptclaudegeminideepseekgrokJNJJohnson & J…231.7spot253.0analysts194207220233246259
Pessimistinen (min)
$178.22
-23.1%
Perus (mediaani)
$221.52
-4.4%
Optimistinen (max)
$215.19
-7.1%

Arvion kehitys AI-mallien arviot ja osakkeen hinta ajan yli

Loading...

Mikä muuttui tänään

Konsensusarvio:226.52→221.52(-2.2%)
CAGR
-0.7pp(1 ↓)
no changemoderated growthvaluation

Mallien erittely

GPT →
Est.
226.52
Ero
-2.2%
Conf
0.80
DCF 215.19 → Kal. 226.52
Avaintekijät
  • Strong product pipeline in innovative medicine segment
  • Ongoing market expansion opportunities
  • Investment in R&D leading to potential revenue growth
Suurin riski
  • Upcoming patent expirations
  • Regulatory challenges
  • Market competition in pharmaceutical sector
Muutos
Key assumptions have remained stable since yesterday, reflecting consistent growth expectations.
Ei edellistä dataa
valuationhealthcarestable
GEMINI →
Est.
221.52
Ero
-4.4%
Conf
0.80
DCF 208.05 → Kal. 221.52
Avaintekijät
  • Diversified portfolio across Innovative Medicine and MedTech segments provide…
  • Strong market position and global brand recognition in the healthcare industry.
  • Continued innovation in key therapeutic areas like oncology, immunology, card…
Suurin riski
  • Potential impact of patent expirations and increased generic competition on key pharmac…
  • Regulatory changes and evolving healthcare policies in major markets affecting product …
  • Challenges in maintaining a robust R&D pipeline to offset mature product declines and d…
Muutos
A slight moderation in the 5-year revenue growth forecast from yesterday, reflecting a more conservative long-term ou…
CAGR
-0.7pp
moderated growth
GROK →
Est.
205.01
Ero
-11.5%
Conf
0.65
DCF 184.46 → Kal. 205.01
Avaintekijät
  • Innovative Medicine segment drives oncology/immunology growth
  • MedTech expansion in robotics and orthopedics
  • Historical 5.6% revenue CAGR anchors future outlook
Suurin riski
  • Patent expirations on key products
  • Healthcare regulatory and pricing pressures
  • Competition in generics/biosimilars
Muutos
Assumptions held steady vs prior day; no material revision to growth, margin, or WACC inputs.
Ei muutosta
no change
DEEPSEEK →
Est.
200.64
Ero
-13.4%
Conf
0.70
DCF 178.22 → Kal. 200.64
Avaintekijät
  • Historical revenue CAGR of 5.6% (2022-2025) provides a baseline for future gr…
  • Innovative Medicine segment pipeline, including oncology and immunology advan…
  • MedTech segment benefits from aging population and surgical procedure volume …
Suurin riski
  • Patent expirations on key drugs could pressure revenue growth
  • Litigation related to talc and opioid cases remains an overhang
  • Pricing pressure from healthcare reforms and drug pricing legislation
Muutos
No material change in assumptions from yesterday's model. Revenue CAGR, EBIT margin, WACC, and terminal growth remain…
Ei muutosta
no change
CLAUDE →EI VALIDI
Est.
231.73
Ero
+0.0%
Conf
0.00
Muutos
Ei edellistä dataa

Arvostusoletukset

DEEPSEEKGEMINIGPTGROK
Liikevaihdon CAGR 5V5.0%6.8%
-0.7pp
6.0%5.5%
EBIT-marginaalitavoite27.0%26.5%31.0%27.0%
WACC8.5%8.3%8.5%8.5%
Terminaalikasvu2.0%2.0%2.0%2.0%

Mitä markkinahinta edellyttäisi?

OletusAI-konsensusMarkkinahinta implikoi
Liikevaihdon CAGR (5v)5.8%8.8%+3.1pp
EBIT-marginaalitavoite27.0%34.4%+7.4pp
WACC8.5%7.5%-1.0pp
Perustuu spot-hintaan $231.73 ja raakaan DCF-malliin (ilman kattoja ja kalibrointia).

Tunnusluvut

EBIT-marginaali26.6%
EBITDA-marginaali35.6%
ROE25.8%
Nettovelka / EBITDA1.0x
P/E26.5x
EV / EBITDA17.2x
P/B6.9x
Analyytikkojen vaihteluväli– – –
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and re
Lähde: Yahoo Finance

Viimeisimmät uutiset

Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know2026-05-21
BAYRY's Kerendia Label Expansion Application Gets Priority Review2026-05-21
A Dividend Portfolio That Beats the Median Household Income in 47 of the 50 States on $1.1 Million Invested2026-05-21
If Treasury Yields Jump Above 4.75%, Here’s What Happens to SDY2026-05-21
Tilaa sähköpostiuutisetIlmainen · Ei roskapostia · Peruuta milloin vain · Tietosuoja
AI Investor Barometer · 2026-05-22
Kaikki sisältö on tekoälymallien tuottamaa ja voi sisältää virheitä. Tämä on kokeellinen työkalu — ei sijoitusneuvontaa, -tutkimusta eikä -suositusta. Käyttöehdot · Tietosuoja